KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $31.8 million.

  • Castle Biosciences' Accumulated Expenses rose 14.78% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 14.78%. This contributed to the annual value of $32.6 million for FY2024, which is 12.47% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Accumulated Expenses is $31.8 million, which was up 27.19% from $25.0 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Accumulated Expenses ranged from a high of $32.6 million in Q4 2024 and a low of $5.2 million during Q1 2021.
  • In the last 3 years, Castle Biosciences' Accumulated Expenses had a median value of $22.4 million in 2023 and averaged $22.9 million.
  • Data for Castle Biosciences' Accumulated Expenses shows a peak YoY skyrocketed of 90.75% (in 2021) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Accumulated Expenses (Quarterly) stood at $15.5 million in 2021, then surged by 57.32% to $24.4 million in 2022, then increased by 18.83% to $28.9 million in 2023, then grew by 12.47% to $32.6 million in 2024, then grew by 14.78% to $31.8 million in 2025.
  • Its Accumulated Expenses stands at $31.8 million for Q3 2025, versus $25.0 million for Q2 2025 and $17.9 million for Q1 2025.